Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis

The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
Mahmoud KiaeiM Flint Beal

Abstract

Accumulating evidence suggests that inflammation plays a major role in the pathogenesis of motor neuron death in amyotrophic lateral sclerosis (ALS). Important mediators of inflammation such as the cytokine tumor necrosis factor-alpha (TNF-alpha) and its superfamily member fibroblast-associated cell-surface ligand (FasL) have been implicated in apoptosis. We found increased TNF-alpha and FasL immunoreactivity in lumbar spinal cord sections of ALS patients and G93A transgenic mice. Both increased TNF-alpha and FasL immunostaining in the lumbar spinal cord of the G93A SOD1 transgenic mice occurred at 40-60 d, well before the onset of symptoms and loss of motor neurons. We tested the neuroprotective effect of thalidomide and its analog lenalidomide, pharmacological agents that inhibit the expression of TNF-alpha and other cytokines by destabilizing their mRNA. Treatment with either thalidomide or lenalidomide attenuated weight loss, enhanced motor performance, decreased motor neuron cell death, and significantly increased the life span in G93A transgenic mice. Treated G93A mice showed a reduction in TNF-alpha and FasL immunoreactivity as well as their mRNA in the lumbar spinal cord. Both compounds also reduced interleukin (IL)-12p...Continue Reading

Citations

Apr 22, 2008·Journal of Neurology·Thomas MeyerPeter Linke
Jun 17, 2010·Journal of Neural Transmission·Ana G BarbeitoSéverine Boillée
Oct 1, 2010·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Marcelo R Vargas, Jeffrey A Johnson
Nov 7, 2009·The Journal of Biological Chemistry·Alexey A TomilovGino A Cortopassi
Jan 10, 2012·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J AebischerC Raoul
Sep 8, 2012·The AAPS Journal·Darlene M RozewskiMitch A Phelps
Nov 4, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Anissa IgoudjilGiovanni Manfredi
Dec 8, 2009·Neuropsychiatric Disease and Treatment·Stefano ZoccolellaPaolo Lamberti
Oct 9, 2013·Cellular and Molecular Life Sciences : CMLS·Federica RizzoEva Hedlund
Apr 12, 2014·Translational Stroke Research·Wanqiu ChenHua Su
Mar 25, 2014·Journal of Neuroinflammation·Ian A Clark, Bryce Vissel
Jul 26, 2012·Neurology Research International·Kalina Venkova-HristovaKenneth Hensley
Aug 27, 2014·BioMed Research International·Ana C CalvoRosario Osta
May 4, 2007·Medical Hypotheses·Elijah W StommelBrent T Harris
Jan 18, 2007·Expert Opinion on Therapeutic Targets·Simonetta Camandola, Mark P Mattson
Aug 3, 2011·Expert Opinion on Emerging Drugs·Ali Aamer Habib, Hiroshi Mitsumoto
Feb 7, 2012·Expert Opinion on Investigational Drugs·John A Morren, Nestor Galvez-Jimenez
May 1, 2015·Expert Opinion on Drug Discovery·Masaaki KonishiJochen Springer
Jul 3, 2007·Expert Opinion on Emerging Drugs·Richard S BedlackMerit E Cudkowicz
Feb 15, 2008·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Sean ScottJames A Heywood
Sep 14, 2007·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Chang ZhouCheng Zhang
Nov 20, 2009·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Stayko SarafovKatja Kollewe
Nov 20, 2009·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Elijah W StommelBrent T Harris
Nov 1, 2013·Drug Discovery Today·Bariş Genç, P Hande Özdinler
Nov 26, 2015·Human Molecular Genetics·Mohammad A EsmaeiliMahmoud Kiaei
Aug 6, 2011·Progress in Neurobiology·Giulietta RiboldiStefania Corti
May 10, 2011·Free Radical Biology & Medicine·Robert A FloydKirk R Maples
Feb 1, 2011·Brain Research·Richard M BlissJean Strahlendorf
Jul 9, 2010·Progress in Neurobiology·Elisabetta Polazzi, Barbara Monti
Sep 29, 2009·Clinical Nutrition : Official Journal of the European Society of Parenteral and Enteral Nutrition·Barkha P Patel, Mazen J Hamadeh

❮ Previous
Next ❯

Related Concepts

Related Feeds

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating genetic alterations in this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.